{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "related-items", "type": "clause", "offset": [43, 56]}, {"key": "to-the-contractor", "type": "clause", "offset": [79, 96]}, {"key": "the-state", "type": "clause", "offset": [123, 132]}, {"key": "basis-of", "type": "clause", "offset": [161, 169]}, {"key": "contractual-provisions", "type": "clause", "offset": [212, 234]}], "samples": [{"hash": "hFyvr1XQtGF", "uri": "/contracts/hFyvr1XQtGF#program-product", "label": "Contractor Agreement", "score": 30.8847885132, "published": true}, {"hash": "ktAjBWSDQJZ", "uri": "/contracts/ktAjBWSDQJZ#program-product", "label": "Supplemental Terms and Conditions", "score": 26.1704311371, "published": true}, {"hash": "e1XKOSyXJoB", "uri": "/contracts/e1XKOSyXJoB#program-product", "label": "Contact Tracing Solution Agreement", "score": 26.1676940918, "published": true}], "size": 78, "snippet": "means programs, routines, subroutines, and related items which are proprietary to the Contractor and which are licensed to the State for its use, usually on the basis of separately stated charges and appropriate contractual provisions.", "hash": "fce697098a733d95d51508649569dd4c", "id": 1}, {"snippet_links": [{"key": "dosage-form", "type": "definition", "offset": [57, 68]}, {"key": "licensed-antibody", "type": "definition", "offset": [82, 99]}, {"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [112, 144]}, {"key": "in-combination", "type": "definition", "offset": [148, 162]}, {"key": "other-active-ingredients", "type": "definition", "offset": [168, 192]}, {"key": "licensed-antibodies", "type": "definition", "offset": [198, 217]}], "samples": [{"hash": "jhIRusgJkF1", "uri": "/contracts/jhIRusgJkF1#program-product", "label": "Global Transaction Agreement (BioAtla, Inc.)", "score": 35.7268981934, "published": true}, {"hash": "fNEj3uA8yKZ", "uri": "/contracts/fNEj3uA8yKZ#program-product", "label": "License Agreement (Context Therapeutics Inc.)", "score": 35.7268981934, "published": true}, {"hash": "d4mcn2DDLH0", "uri": "/contracts/d4mcn2DDLH0#program-product", "label": "License Agreement (BioAtla, Inc.)", "score": 35.7268981934, "published": true}], "size": 4, "snippet": "means all pharmaceutical preparations or products in any dosage form containing a Licensed Antibody as the sole active pharmaceutical ingredient or in combination with other active ingredients. The Licensed Antibodies are listed in Schedule 1(a);", "hash": "7c3fe2206c3a454e7ecb16a041949033", "id": 2}, {"snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [10, 32]}, {"key": "during-the-research-term", "type": "clause", "offset": [47, 71]}, {"key": "with-respect-to", "type": "clause", "offset": [102, 117]}, {"key": "program-compound", "type": "definition", "offset": [120, 136]}, {"key": "line-extensions", "type": "clause", "offset": [217, 232]}], "samples": [{"hash": "lzalhxEfKMM", "uri": "/contracts/lzalhxEfKMM#program-product", "label": "Collaboration and License Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "ibPQWQyHuAE", "uri": "/contracts/ibPQWQyHuAE#program-product", "label": "Collaboration and License Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "29hSwPCDsVk", "uri": "/contracts/29hSwPCDsVk#program-product", "label": "Collaboration and License Agreement (Tularik Inc)", "score": 18.0, "published": true}], "size": 3, "snippet": "means any pharmaceutical product which results during the Research Term [ * ] from research conducted with respect to a Program Compound. Each Program Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.", "hash": "2ca381762e83e647f7ef506379e0c188", "id": 3}, {"snippet_links": [{"key": "related-items", "type": "clause", "offset": [43, 56]}, {"key": "to-contractor", "type": "clause", "offset": [79, 92]}, {"key": "basis-of", "type": "clause", "offset": [155, 163]}, {"key": "contractual-provisions", "type": "clause", "offset": [206, 228]}], "samples": [{"hash": "9eIrg6tpYWg", "uri": "/contracts/9eIrg6tpYWg#program-product", "label": "Contract for Solicitation No. 2021 9089", "score": 24.9931545258, "published": true}, {"hash": "d1eiElQCynZ", "uri": "/contracts/d1eiElQCynZ#program-product", "label": "Standard Agreement", "score": 23.8911705017, "published": true}], "size": 3, "snippet": "means programs, routines, subroutines, and related items which are proprietary to Contractor and which are licensed to CalPERS for its use, usually on the basis of separately stated charges and appropriate contractual provisions.", "hash": "c6d4cb4c555055568dc8de84bbaa36ec", "id": 4}, {"snippet_links": [{"key": "comprised-of", "type": "definition", "offset": [80, 92]}, {"key": "program-molecule", "type": "definition", "offset": [107, 123]}, {"key": "active-ingredient", "type": "definition", "offset": [174, 191]}, {"key": "other-component", "type": "definition", "offset": [271, 286]}], "samples": [{"hash": "7wjum7L7w6e", "uri": "/contracts/7wjum7L7w6e#program-product", "label": "Research Collaboration and License Agreement (RayzeBio, Inc.)", "score": 34.6427116394, "published": true}, {"hash": "6Y91JoYgg0W", "uri": "/contracts/6Y91JoYgg0W#program-product", "label": "Research Collaboration and License Agreement (RayzeBio, Inc.)", "score": 33.1122512817, "published": true}], "size": 3, "snippet": "means any pharmaceutical preparation, substance, formulation or dosage which is comprised of or contains a Program Molecule (whether or not such Program Molecule is the sole active ingredient and whether or not such Program Molecule is conjugated to or combined with any other component or reagent).", "hash": "5c241cebaba6c6046c06d39a22c60990", "id": 5}, {"snippet_links": [{"key": "architectural-paint", "type": "definition", "offset": [10, 29]}, {"key": "the-program", "type": "clause", "offset": [42, 53]}, {"key": "architectural-coatings", "type": "definition", "offset": [92, 114]}, {"key": "original-equipment", "type": "clause", "offset": [189, 207]}, {"key": "specialty-coatings", "type": "definition", "offset": [212, 230]}, {"key": "the-act", "type": "clause", "offset": [264, 271]}, {"key": "program-plan", "type": "definition", "offset": [305, 317]}], "samples": [{"hash": "fSWdQoUtrAg", "uri": "/contracts/fSWdQoUtrAg#program-product", "label": "Paintcare Remitter Agreement", "score": 21.4516658783, "published": true}, {"hash": "4aX6CVYipuS", "uri": "/contracts/4aX6CVYipuS#program-product", "label": "Paintcare Remitter Agreement", "score": 21.4516658783, "published": true}], "size": 3, "snippet": "means the architectural paint included in the Program, and defined as interior and exterior architectural coatings sold in containers of five gallons or less, but does not mean industrial, original equipment, or specialty coatings under Section 2(1)(a) and (b) of the Act, and as further described in the Program Plan.", "hash": "7c35fe646eb1b7f1c6d1232757343aac", "id": 6}, {"snippet_links": [{"key": "active-ingredient", "type": "definition", "offset": [36, 53]}, {"key": "program-compound", "type": "definition", "offset": [56, 72]}], "samples": [{"hash": "7TYfZT5QQf1", "uri": "/contracts/7TYfZT5QQf1#program-product", "label": "Master Research and Collaboration Agreement (Vividion Therapeutics, Inc.)", "score": 32.4798088074, "published": true}, {"hash": "kx2QDOgD4UT", "uri": "/contracts/kx2QDOgD4UT#program-product", "label": "Master Research and Collaboration Agreement (Vividion Therapeutics, Inc.)", "score": 32.3073234558, "published": true}], "size": 3, "snippet": "means a product that contains as an active ingredient a Program Compound, in all forms, presentations, and formulations (including all manners of delivery and dosage).", "hash": "cacfe2627000253838c80c68adb1153b", "id": 7}, {"snippet_links": [{"key": "british-columbia", "type": "clause", "offset": [78, 94]}, {"key": "recycling-regulation", "type": "definition", "offset": [95, 115]}, {"key": "stewardship-plan", "type": "definition", "offset": [128, 144]}], "samples": [{"hash": "7PPcJzj228c", "uri": "https://opeicreporting.ca/documents/210104%20OPEIC%20EHF%20Rules%20and%20Procedures%20Policy.pdf", "label": "opeicreporting.ca", "score": 8.5044488907, "published": false}, {"hash": "dj2dwNEHcsV", "uri": "https://www.opeicreporting.ca/OPEIC%20EHF%20Rules%20and%20Procedures%20Policy.pdf", "label": "www.opeicreporting.ca", "score": 5.9226555824, "published": false}], "size": 2, "snippet": "means products that are accepted for recycling by OPEIC, as defined under the British Columbia Recycling Regulation and OPEIC\u2019s Stewardship Plan.", "hash": "f903cb0bba674a64e2ed61fb91f4a798", "id": 8}, {"snippet_links": [{"key": "section-51", "type": "clause", "offset": [36, 47]}], "samples": [{"hash": "l3N2xLPkn1R", "uri": "/contracts/l3N2xLPkn1R#program-product", "label": "Collaboration Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "i2zXufzNYML", "uri": "/contracts/i2zXufzNYML#program-product", "label": "Collaboration Agreement (Tularik Inc)", "score": 18.0, "published": true}], "size": 2, "snippet": "shall have the meaning set forth in Section 5.1.", "hash": "9c775924d9608ac570d02b9e3404e133", "id": 9}, {"snippet_links": [{"key": "software-programs", "type": "definition", "offset": [19, 36]}, {"key": "exhibit-a", "type": "clause", "offset": [95, 104]}, {"key": "from-third-parties", "type": "clause", "offset": [148, 166]}, {"key": "right-to-use-and-distribute", "type": "clause", "offset": [197, 224]}], "samples": [{"hash": "jJllkSvGj0B", "uri": "/contracts/jJllkSvGj0B#program-product", "label": "Software License Agreement (Applied Intelligence Group Inc)", "score": 18.0, "published": true}, {"hash": "glGCBtjU6Xi", "uri": "/contracts/glGCBtjU6Xi#program-product", "label": "Asset Purchase Agreement (Applied Intelligence Group Inc)", "score": 18.0, "published": true}], "size": 2, "snippet": "means the computer software programs, documentation, interfaces and related code identified in Exhibit A attached hereto. This may include software from third parties from whom Ijob has obtained a right to use and distribute.", "hash": "3f25364a757c331f86cc0d304b555ff8", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYcHJvZ3JhbS1wcm9kdWN0IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Program Product", "size": 129, "snippet": "means programs, routines, subroutines, and related items which are proprietary to the Contractor and which are licensed to the State for its use, usually on the basis of separately stated charges and appropriate contractual provisions.", "id": "program-product", "examples": ["Subject to Section 7.3.5 (Cooperation), as among the Parties, \u2587\u2587\u2587\u2587\u2587 has the first right, but not the obligation, to bring and control any legal action in connection with any Infringement of any (a) MeiraGTx Prosecuted Patent against any Infringement that is competitive with any <strong>Program Product</strong> or (b) any Lilly Prosecuted Patent.", "Subject to Section 7 (New MeiraGTx In-License Agreements), MeiraGTx shall be responsible for all payments owed to Third Parties under any license or other agreement with respect to any material, Know-How or Patent licensed to Lilly hereunder or pursuant to which MeiraGTx or any of its Affiliates has rights with respect to any <strong>Program Product</strong> or the Exploitation thereof, entered into prior to, on or after the Effective Date by or on behalf of MeiraGTx or any of its Affiliates.", "Until the First Commercial Sale of a <strong>Program Product</strong> in the Territory, Lilly shall provide MeiraGTx with a high-level written report summarizing its material development activities with respect to each <strong>Program Product</strong> on an [***].", "Lilly may, [***] in its sole discretion and without cause, terminate this Agreement on a <strong>Program Product</strong>-by-<strong>Program Product</strong> basis or country-by-country basis upon (a) [***] prior written notice to MeiraGTx if such termination notice is delivered prior to the First Commercial Sale of such <strong>Program Product</strong> and (b) [***] prior written notice to MeiraGTx if such termination notice is delivered after the First Commercial Sale of such <strong>Program Product</strong>.", "If \u2587\u2587\u2587\u2587\u2587 is precluded from taking a Royalty reduction in a Calendar Quarter by operation of the limitation set forth in this Section 6.5.5 (Floor), then \u2587\u2587\u2587\u2587\u2587 will be entitled to carry forward the amount of such reduction that \u2587\u2587\u2587\u2587\u2587 was unable to take during a Calendar Quarter with respect to such Economic-Bearing <strong>Program Product</strong> to future Calendar Quarters and for such Economic-Bearing <strong>Program Product</strong> until Lilly has taken the amount of such reduction in full.", "Notwithstanding the foregoing with respect to any Gene Therapy Product or Economic-Bearing Capsid Product in any Calendar Quarter, the Royalties that would otherwise have been due under Section 6.4.3 (Royalty Rates) with respect to such Economic-Bearing <strong>Program Product</strong> during such Calendar Quarter shall not be reduced by more than [***] percent ([***]%) as a result of reductions made pursuant to [***]."], "related": [["licensed-product", "Licensed Product", "Licensed Product"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["hemp-product", "Hemp product", "Hemp product"], ["new-product", "New Product", "New Product"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"]], "related_snippets": [], "updated": "2026-04-01T04:22:47+00:00"}, "json": true, "cursor": ""}}